Loading
A phase 2 trial in lung cancer, run by SUNHO（China）BioPharmaceutical CO., Ltd., not yet recruiting.
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07076095 by SUNHO（China）BioPharmaceutical CO., Ltd., with a registry enrolment figure of 200 participants, started 2025-08-01 and due to reach its primary completion in 2028-08-01. Interventions recorded: IBB0979; topotecan hydrochloride for injection. Conditions listed: Small Cell Lung Cancer. Primary outcome: Frequency of adverse events (AEs) and SAEs (Phase II). Lung eligibility wording from the registry: "Histologically confirmed SCLC". No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.